4 ms·
not to mention the revolving door between drug company execs and regulators - which is ripe for conflicts of interest.
by ejb999 3y ago
not to mention the revolving door between drug company execs and regulators - which is ripe for conflicts of interest.
- azinman2 3y agoWhat percent of FDA scientists and committee members who are in charge of approving drugs have been part of the “revolving door?” And how do we know this is inherently bad? It may be, but I can also see how niche expertise would cause you to float between entities as appropriate. Keep in mind 90% of drugs fail clinical trials. The situation cannot be THAT bad.
- mlyle 3y agoThe specific cases we're talking about is where FDA political appointees have overridden and/or appointed new advisory committees for a redo.